Zoetis exposed?

Discussion in 'Valeant Pharmaceuticals' started by Anonymous, Nov 20, 2014 at 9:55 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Zoetis Inc. (ZTS) issued 2015 earnings guidance below expectations. Additionally, the company announced a $500 million shares repurchase program.
     

  2. Anonymous

    Anonymous Guest

    What are you afraid of? Ackman knows there are no synergies between ZTS and VRX. ZTS has other opportunities...
    As to your "below expectations..." whatever... you can't go against their credibility as they have consistently delivered so far
     
  3. Anonymous

    Anonymous Guest

    Vrx said it has no interest
     
  4. Anonymous

    Anonymous Guest

    Pearson has no interest in collaborating with Ackman again on a deal for Valeant, but he is still interested in Zoetis, or another pharma company with domestic pet focus. I wonder if during their heart-to-heart, thumb-twiddling super-secret talks a year ago, as they plotted to subvent SEC law to gain a takeover position in AGN, if Pearson didn't dribble out his strategy about making domestic pet pharma one of the items on his target wish list; and then literally at the moment their joint Allergan project imploded when Actavis came in as the white knight, that is the same moment that Ackman announced his huge position in Zoetis...

    Pearson requires a huge learning curve.